Founded in 2007, Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, its joint venture Smart Health, dedicated to the roll-out of digital medical testing centres in Saudi Arabia; and Klea Pharmaceuticals, a subsidiary dedicated to the commercialisation of a portfolio of licensed medicines in the Middle East and Africa.

Employees

Sector

Healthcare Facilities & Services

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 15:55:10 29/06/2026 +04			5-day change	1st Jan Change
0.1830 ^EUR	-56.12%		0.00%	-

06-11	Klea Holding SA Announces the Launch of Its New Subsidiary, Klea Pharmaceuticals	CI
06-11	Klea Launches Medicine Distribution Business for Middle East, Africa	MT

Market Cap	58.33M 66.52M 53.76M 50.33M 94.39M 6.28B 96.35M 646M 250M 3.1B 250M 244M 10.75B	P/E 2024	44.3x	P/E 2025	31.3x
Enterprise Value	58.45M 66.67M 53.88M 50.44M 94.59M 6.29B 96.55M 648M 251M 3.11B 250M 245M 10.78B	EV / Sales 2024	3.3x	EV / Sales 2025	3.04x
Free-Float	99.83%	Yield 2024 *	-	Yield 2025	-

06-11	Klea Holding SA Announces the Launch of Its New Subsidiary, Klea Pharmaceuticals	CI
06-11	Klea Launches Medicine Distribution Business for Middle East, Africa	MT
06-11	Klea Holding announces the launch of its new subsidiary
04-23	Klea Holding SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-01	Klea Holding Establishes Klea Pharmaceuticals and Expands Healthcare Operations in Middle East and Africa	CI
04-01	Klea Holding SA acquired New Licences and Pharmaceutical Assets for AED 8.5 million.	CI
01-19	Klea Holding Increases Annual Revenue by 28%
01-19	Klea Holding SA Reports Unaudited Consolidated Sales Results for the Year Ended December 31, 2025	CI
01-19	Klea Holding SA to Open First Digital Medical Centre in Saudi Arabia in March/April 2026	CI
27/10/25	Klea Holding Strengthens Its Presence in Dubai with Its First Strategic Real Estate Investment in the Lumena Alta Project	CI
27/10/25	Klea Holding Buys Office Space at Skyscraper Project in Dubai	MT
19/09/25	Klea Holding SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
18/08/25	Klea Holding SA commences an Equity Buyback Plan for 30,751,431 shares, representing 10% of its issued share capital for ?46.13 million, under the authorization approved on June 10, 2025.	CI

06-11	Klea Holding : Klea Pharmaceuticals launch its business with a strong partner	AT
04-23	Klea : reports record results in 2025 and demonstrates remarkable resilience in Q1 2026	PU
04-23	Klea Holding : Klea Holding reports record results in 2025 and demonstrates remarkable resilience in Q1 2026	AT
04-01	Klea Holding : Klea Holding is accelerating its diversification into the healthcare sector with the creation of Klea Pharmaceuticals	AT
01-19	Klea Holding : Klea Holding reports profitable growth of 34% in turnover in 2025 at constant exchange rates	AT

Visiomed Group Stock London S.E.

Stocks

0D13

FR0013481835

Healthcare Facilities & Services

Valuation: Visiomed Group

Chart: Visiomed Group

Latest news : Visiomed Group

Analysts' recommendations: Visiomed Group

Press Releases: Visiomed Group

News in other languages: Visiomed Group

Quotes and Performance

Managers and Directors: Visiomed Group

Other Healthcare Facilities & Services

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Klea Holding : Déclaration des transactions sur actions propres
06-11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
06-11	Klea Holding annonce le démarrage de sa nouvelle filiale
06-11	Une bonne grosse purge avant SpaceX
06-11	Klea Holding : Klea Pharmaceuticals annonce le démarrage de son activité avec un puissant partenaire

Manager	Title	Age	Since
Clement Pacaud CEO	Chief Executive Officer	36	22/01/2024
Jérôme Fabreguettes-Leib IRC	Investor Relations Contact	-	-
Thomas Picquette CEO	Chief Executive Officer	-	01/04/2022

Director	Title	Age	Since
Guillaume Bremond CHM	Chairman	-	-
Anne Gaignard BRD	Director/Board Member	-	01/04/2022
Paul Amsellem BRD	Director/Board Member	51	14/06/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISIOMED GROUP	-56.12%	0.00%	-	-	66.52M
CVS HEALTH CORPORATION	-0.31%	+6.12%	+52.34%	+53.13%	133B
HCA HEALTHCARE, INC.	+1.22%	+4.40%	+3.26%	+30.77%	86.89B
FRESENIUS SE & CO. KGAA	-0.79%	-0.18%	-7.52%	+58.39%	25.58B
QUEST DIAGNOSTICS INCORPORATED	+1.76%	+7.63%	+18.02%	+47.89%	23.23B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.85%	-1.40%	-21.79%	-27.74%	19.83B
TENET HEALTHCARE CORPORATION	+2.75%	+9.52%	+8.85%	+136.99%	16.28B
REDE D'OR SÃO LUIZ S.A.	+0.46%	+3.30%	-0.54%	+8.47%	14.78B
DAVITA INC.	+1.72%	+4.39%	+53.20%	+122.29%	13.93B
FRESENIUS MEDICAL CARE AG	-0.49%	-1.45%	-16.44%	-5.77%	12.52B
Average	-5.09%	+3.72%	+9.93%	+47.16%	38.46B
Weighted average by Cap.	+0.30%	+4.63%	+22.29%	+45.61%

	2024	2025
Net sales	17.26M 19.69M 15.91M 14.89M 27.93M 1.86B 28.51M 191M 73.99M 918M 73.92M 72.3M 3.18B	22.17M 25.28M 20.43M 19.13M 35.87M 2.38B 36.61M 246M 95.02M 1.18B 94.93M 92.86M 4.09B
Net income	1.4M 1.6M 1.3M 1.21M 2.27M 151M 2.32M 15.57M 6.02M 74.71M 6.02M 5.89M 259M	2.28M 2.6M 2.1M 1.97M 3.69M 245M 3.77M 25.27M 9.78M 121M 9.77M 9.56M 421M
Net Debt	2.58M 2.94M 2.37M 2.22M 4.17M 277M 4.25M 28.53M 11.04M 137M 11.03M 10.79M 475M	125K 143K 115K 108K 202K 13.45M 206K 1.38M 536K 6.65M 535K 524K 23.05M